UC-Led Obesity Research Finds Leptin Hormone Isn't the Overeating Culprit
CINCINNATI—For years, scientists have pointed to leptin resistance as a possible cause of obesity. Research led by investigators at the University of Cincinnati (UC) Metabolic Diseases Institute, however, found that leptin action isn't the culprit.
"Restoring leptin action will not be effective at reducing obesity because leptin action is normal as opposed to being impaired in obesity," says assistant professor Diego Perez-Tilve, PhD, who directed the study "Diet-Induced Obese Mice Retain Endogenous Leptin Action" which appeared in the science journal Cell Metabolism on May 14, 2015.
Leptin is a hormone that plays a role in appetite and weight control. It is produced, Perez-Tilve says, when we are well fed, and it signals to the brain that there is ample energy and therefore reduces eating.
Leptin has been a hormone of interest since 1994, he says, when scientists discovered that a particular strain of obese mouse couldn't produce leptin at all.
"That mouse was very obese because it was hungry all the time. When they treated the mouse withleptin, it stopped eating so much and started losing weight."
Perez-Tilve says scientists were initially puzzled because obese persons have leptin levels far higher than persons of average weight. They theorized that the body was making extra leptin to combat obesity and that the obese patients must therefore need more leptin than persons of average weight to signal the brain to stop eating. However, in human preclinical trials, "giving obese patients more leptin didn't work ? they ate the same and remained obese, so it was concluded that obesity was a state of leptin resistance," he says.
In the UC study, funded by the National Institutes of Health, the team headed by Perez-Tilve took a different approach. They blocked leptin action in both lean and obese mice. The results were that both sets of mice ate more and gained weight to the same extent, proving that "leptin action was not impaired in the obese mouse."
With obesity affecting more than one-third of Americans and taking a toll on the nation's health care system, Perez-Tilve says the results of this study show "we need to change our way of thinking about how to use leptin as a potential target for therapy to treat obesity."
Perez-Tilve is a researcher in the UC College of Medicine's Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Designing with cancer patients' needs in focus
August 27, 2026
Kristina Shin is designing garments that prioritize the comfort, function and confidence of breast cancer patients, addressing a need often overlooked by traditional fashion.